Abstracts tagged "methotrexate (MTX) and pediatric rheumatology"

Abstract Number: 2271 • ACR/ARHP Annual Meeting 2017
Safety of Adalimumab±Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Hermine I. Brunner¹, Nicola Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Daniel J Kingsbury⁹, Katherine Marzan¹⁰, Pierre Quartier¹¹, Kirsten Minden¹², Elizabeth Chalom¹, Gerd Horneff¹³, Rolf M. Kuester¹⁴, Jason A Dare¹⁵, Mareike Bereswill¹⁶, Jasmina Kalabic¹⁶, Hartmut Kupper¹⁶, Daniel J Lovell¹ and Alberto Martini², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO-IRCCS Gaslini, Genova, Italy, ³University of Washington School of Medicine and Seattle Children's Hospital, Bayside, NY, ⁴Akron Children's Hospital, Akron, OH, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶University of Utah, Department of Pediatrics, Salt Lake City, UT, ⁷The Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NJ, ⁹Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ¹⁰Children's Hospital Los Angeles, Los Angeles, CA, ¹¹Hopital Necker-Enfants Malades, Paris, France, ¹²Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹³Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁴Orthopädiezentrum Altona, Hamburg, Germany, ¹⁵Arkansas Children’s Hospital, Little Rock, AR, ¹⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: JIA is the most common chronic inflammatory rheumatic disease of childhood. Due to their known safety and efficacy, TNF inhibitors are used for long-term…
Abstract Number: 2001 • ACR/ARHP Annual Meeting 2012
Methotrexate and Injectable Tumor Necrosis Factor Alpha Inhibitor Adherence and Persistence in Children with Rheumatic Diseases
Sarah Ringold¹, Shannon Grant², Charmaine Girdish³, Carol A. Wallace⁴ and Sean Sullivan⁵, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Axio Research LLC, Seattle, WA, ³Research, CVS Caremark, Scottsdale, AZ, ⁴Pediatrics, Seattle Childrens Hospital, Seattle, WA, ⁵Health Sciences Building, University of Washington, Seattle, WA
Background/Purpose: Medication adherence and persistence have been demonstrated to have important implications for treatment effectiveness, cost, and safety. Methotrexate is one of the most commonly…
Abstract Number: 1151 • ACR/ARHP Annual Meeting 2012
Low-Dose Methotrexate and the Selective Accumulation of Intracellular Aminoimidazolecarboxamide Ribotide
Ryan S. Funk¹, Leon van Haandel¹, Mara L Becker² and J.S. Leeder¹, ¹Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospital, Kansas City, MO, ²Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Current evidence suggests that the anti-folate methotrexate (MTX) mediates its anti-inflammatory effects through inhibition of the purine synthesis pathway causing the accumulation of…